This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
A simple blood test detects over 30 types of cancers
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Subscribe To Our Newsletter & Stay Updated
